Regulating CD154 mRNA Translation via CA-Dinucleotide Repeat Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to effectively regulate CD154 mRNA translation, which is critical for immune responses and is involved in various autoimmune and inflammatory diseases, due to the instability and complex regulation of its expression.
Innovation Solution
Identifying and targeting the CA-dinucleotide rich sequences in the CD154 3′-untranslated region and modulating the activity of hnRNP L protein to control mRNA translation, using agents that bind to these sequences or affect hnRNP L levels, thereby regulating CD154 expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cyclosporine and glucocorticoids are used to block CD154 induction, then CD154 expression is inhibited, but cytokine production is also inhibited
Solution Approach 1:
The patent segments the regulation pathways by identifying distinct mechanisms for CD154 mRNA stability versus cytokine production. By targeting specific 3'-UTR sequences and RNA-binding proteins (hnRNP L, PTB family) that regulate CD154 translation independently, the invention separates CD154 regulation from cytokine production pathways, allowing selective inhibition of CD154 without affecting cytokine synthesis
Solution Approach 2:
The patent introduces small molecule compounds as intermediaries that specifically bind to hnRNP L or PTB family proteins to modulate their RNA-binding activity. These intermediary molecules enable selective control of CD154 translation by disrupting protein-RNA interactions at the 3'-UTR level, without interfering with the transcriptional or translational machinery required for cytokine production
2Quantity of substance
If maximal CD154 expression is achieved through PMA and ionomycin stimulation, then CD154 levels are increased, but the pathway complexity increases
Solution Approach 1:
The patent extracts the critical regulatory element (CA-dinucleotide repeat in 3'-UTR) from the complex stimulation pathway. By identifying this specific sequence motif as the key control point for CD154 translation, the invention simplifies the regulation mechanism to a targetable molecular feature that can be controlled by small molecules binding to RNA-binding proteins, bypassing the need for complex pharmacologic stimulation
Solution Approach 2:
The patent changes the regulatory parameter from transcriptional control (requiring PMA/ionomycin) to post-transcriptional control via RNA stability and translation efficiency. By modulating the activity of RNA-binding proteins that interact with the 3'-UTR CA-repeat, the system achieves CD154 expression control through a different molecular parameter (protein-RNA binding affinity) that is more amenable to pharmacologic modulation
3Quantity of substance
If CD154 mRNA stability is increased, then CD154 expression is enhanced, but mRNA turnover rate increases
Solution Approach 1:
The patent inverts the conventional approach by instead of trying to stabilize mRNA, it targets the translation efficiency and nuclear export control through hnRNP L binding to the 3'-UTR. This inverted strategy allows CD154 protein expression to be enhanced through increased translation initiation and nuclear-cytoplasmic transport, while the mRNA itself maintains its naturally short half-life, avoiding the instability problem
Data Source
AI summary
Compositions and methods for regulating CD154 gene expression are provided that rely on the interaction of hnRNP L with the CA-dinucleotide rich sequence of the 3′-untranslated region of CD154.